MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Sanofi

Geschlossen

54.58 1.19

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

53.9

Max

55.68

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.3B

499M

Verkäufe

-6.5B

7.6B

KGV

Branchendurchschnitt

23.205

63.778

EPS

0.682

Dividendenrendite

3.67

Gewinnspanne

6.539

Angestellte

82,878

EBITDA

-3.7B

563M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+20.02% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.67%

2.39%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.5B

136B

Vorheriger Eröffnungskurs

53.39

Vorheriger Schlusskurs

54.58

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Sanofi Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. März 2025, 06:43 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

3. Feb. 2025, 13:19 UTC

Akquisitionen, Fusionen, Übernahmen

L'Oreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group -- Update

3. Feb. 2025, 09:31 UTC

Akquisitionen, Fusionen, Übernahmen

Correction to L'Oreal article

3. Feb. 2025, 07:09 UTC

Akquisitionen, Fusionen, Übernahmen

L'Oreal Agrees to Sell Back 2.3% Stake in Sanofi for $3.1 Billion

30. Jan. 2025, 11:09 UTC

Ergebnisse

Correction to Sanofi Article

3. Apr. 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2. Apr. 2025, 09:27 UTC

Heiße Aktien

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

20. März 2025, 06:05 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20. März 2025, 06:05 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20. März 2025, 06:04 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Pay $600M Upfront

20. März 2025, 06:02 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20. März 2025, 06:00 UTC

Akquisitionen, Fusionen, Übernahmen

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

19. Feb. 2025, 06:35 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19. Feb. 2025, 06:34 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19. Feb. 2025, 06:34 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19. Feb. 2025, 06:33 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19. Feb. 2025, 06:33 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19. Feb. 2025, 06:33 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19. Feb. 2025, 06:32 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19. Feb. 2025, 06:31 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi, CD&R Sign Opella Share Purchase Agreement

3. Feb. 2025, 06:37 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Says Transaction Is Part of Its Share Buyback Program

3. Feb. 2025, 06:35 UTC

Akquisitionen, Fusionen, Übernahmen

L'Oreal: Sale Should Be Finalized in Coming Days

3. Feb. 2025, 06:35 UTC

Akquisitionen, Fusionen, Übernahmen

L'Oreal: Transaction Will Optimize Balance Sheet, Diversify Financing Sources

3. Feb. 2025, 06:34 UTC

Akquisitionen, Fusionen, Übernahmen

L'Oreal Says It Remains Important Sanofi Shareholder, Fully Supports Strategy

3. Feb. 2025, 06:33 UTC

Akquisitionen, Fusionen, Übernahmen

L'Oreal Will Own 7.2% of Sanofi's Capital, 13.1% of Voting Rights After Transaction

3. Feb. 2025, 06:32 UTC

Akquisitionen, Fusionen, Übernahmen

L'Oreal Selling 2.3% Stake in Sanofi for EUR101.50 a Share

3. Feb. 2025, 06:31 UTC

Akquisitionen, Fusionen, Übernahmen

L'Oreal to Sell Sanofi Stake for EUR3B

3. Feb. 2025, 06:31 UTC

Akquisitionen, Fusionen, Übernahmen

L'Oreal to Sell Sanofi Stake Back to Sanofi

30. Jan. 2025, 10:47 UTC

Market Talk
Ergebnisse

Sanofi's Buyback and Increased R&D Spending Are Positive -- Market Talk

30. Jan. 2025, 10:31 UTC

Market Talk
Ergebnisse

Sanofi's Lung Drug Beyfortus Sales Beat Stands Out Among 4Q Results -- Market Talk

Peer-Vergleich

Kursveränderung

Sanofi Prognose

Kursziel

By TipRanks

20.02% Vorteil

12-Monats-Prognose

Durchschnitt 64.75 USD  20.02%

Hoch 67 USD

Tief 63 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sanofi – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

3

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

N/A / 55.4Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Strong Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.